REGENERON PHARMACEUTICALS, INC.
For the period ended Jun 30, 2026. Filed Jul 30, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Jul 30, 2026
REGN$916.06-0.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)
(In millions, except per share data)
| June 30, | December 31, | |
|---|---|---|
| 2026 | 2025 | |
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | $2,455.8 | $3,118.1 |
| Marketable securities | 5,538.8 | 5,487.1 |
| Accounts receivable, net | 6,565.4 | 5,741.1 |
| Inventories | 3,084.3 | 3,200.8 |
| Prepaid expenses and other current assets | 801.7 | 474.8 |
| Total current assets | 18,446.0 | 18,021.9 |
| Marketable securities | 9,828.3 | 10,260.6 |
| Property, plant, and equipment, net | 5,458.9 | 5,120.4 |
| Intangible assets, net | 1,309.8 | 1,257.4 |
| Deferred tax assets | 4,381.4 | 4,077.2 |
| Other noncurrent assets | 2,306.2 | 1,821.2 |
| Total assets | $41,730.6 | $40,558.7 |
| LIABILITIES AND STOCKHOLDERS' EQUITY | ||
| Current liabilities: | ||
| Accounts payable | $1,159.3 | $939.0 |
| Accrued expenses and other current liabilities | 2,966.5 | 2,876.4 |
| Finance lease liabilities | 720.0 | — |
| Deferred revenue | 684.8 | 553.0 |
| Total current liabilities | 5,530.6 | 4,368.4 |
| Long-term debt | 1,986.6 | 1,985.9 |
| Finance lease liabilities | — | 720.0 |
| Deferred revenue | 220.4 | 208.7 |
| Other noncurrent liabilities | 2,281.6 | 2,018.8 |
| Total liabilities | 10,019.2 | 9,301.8 |
| Stockholders' equity: | ||
| Preferred Stock, par value $.01 per share; 30.0 shares authorized; shares issued and outstanding - none | — | — |
| Class A Stock, convertible, par value $.001 per share; 40.0 shares authorized; shares issued and outstanding - 1.8 in 2026 and 2025 | — | — |
| Common Stock, par value $.001 per share; 320.0 shares authorized; shares issued - 138.0 in 2026 and 137.6 in 2025 | 0.1 | 0.1 |
| Additional paid-in capital | 14,700.6 | 13,995.0 |
| Retained earnings | 37,621.4 | 35,797.1 |
| Accumulated other comprehensive (loss) income | (35.8) | 77.5 |
| Treasury Stock, at cost; 36.4 shares in 2026 and 33.7 shares in 2025 | (20,574.9) | (18,612.8) |
| Total stockholders' equity | 31,711.4 | 31,256.9 |
| Total liabilities and stockholders' equity | $41,730.6 | $40,558.7 |
| The accompanying notes are an integral part of the financial statements. | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.